Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 22, Abbott ...
Abbott Laboratories posted its largest-ever quarter for rapid diagnostics, according to a news release from data analytics and consulting firm GlobalData. The company’s rapid diagnostics segment sold ...
The Abbott Laboratories logo is displayed at the company's booth during the Consumer Electronics Show (CES) on January 5, 2022 in Las Vegas, Nevada. (Photo by Patrick T. FALLON / AFP) (Photo by ...
Wednesday, Abbott Laboratories (NYSE:ABT) reported first-quarter sales of $9.96 billion, up 10.8% on an organic basis for the underlying base business, beating the consensus of $9.88 billion. Reported ...
Abbott’s ABT first-quarter results demonstrated underlying strength even as the diagnostics segment saw significant declines on diminishing demand for COVID-19 tests. As these dynamics were already ...
StockStory.org on MSN
Abbott Laboratories (ABT): Buy, sell, or hold post Q3 earnings?
Over the past six months, Abbott Laboratories’s shares (currently trading at $125.45) have posted a disappointing 7.9% loss, ...
In 2013, Abbott Labs shifted to focus on generics, medical devices, diagnostics, and nutrition. Since then, it has grown its business and become much more robust and diverse. While it has benefited ...
Abbott Laboratories reported a 4% increase in quarterly sales, totalling $10.4 billion. The company released its latest earnings report Thursday and subsequently revised its full-year financial ...
Zacks Investment Research on MSN
Here is what to know beyond why Abbott Laboratories (ABT) is a trending stock
Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Abbott Labs has continued to lag competitors like Boston Scientific and Stryker that are seen as more innovative and more likely to generate attractive revenue growth and margins. I think Abbott could ...
Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens.
Abbott Laboratories must pay $495 million in damages in the case of a girl who developed a serious gastrointestinal disease as a premature infant after consuming Abbott formula, a Missouri jury ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results